The number of patients with urothelial carcinoma (UC) is high, with a corresponding demand
for detecting UC easily and non-invasively. Cystoscopy and urine cytology, with widely …

Bladder cancer (BC) is classified as non-muscle-invasive BC (NMIBC) or muscle-invasive
BC (MIBC). Because the recurrence and mortality rates of BC are high, suitable biomarkers …

As the recurrence and mortality rates of bladder cancer are high, research is needed to find
suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug …

Precision medicine is designed to tailor treatments for individual patients by factoring in
each person's specific biology and mechanism of disease. This paradigm shifted from a “one …

Background We evaluated the use of UroVysion fluorescence in situ hybridization tests to
detect the intravesical recurrence of bladder cancer during follow-up after a transurethral …

BACKGROUND The annual incidence of urothelial carcinoma continues to increase, and it
is projected that greater than 70,000 new cases will occur in the year 2015. However, as …

Tumours of the urinary tract are the fifth most frequent type of cancer. The most common
types are urothelial tumours, among which, non-invasive urothelial neoplasms represent …

Objective: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor
fluorescence in situ hybridization (FISH). It has been used successfully in the USA following …

Urine cytology is a non-invasive test used in combination with cystoscopy for screening and
follow-up of urothelial carcinoma (UC). Although cytology can be used to efficiently identify …

The cytological examination of cavity fluids has limited sensitivity in the diagnosis of
malignancy. Aneuploidy, which is commonly observed in neoplastic cells, could potentially …